Glucagon like Peptide 1 News and Research

RSS

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

Study delves into the concept of 'food noise,' referring to persistent thoughts about eating, and assesses its impact on eating behaviors and obesity treatments. It explores how GLP-1RAs, a class of drugs used for weight management, might influence food cue reactivity, potentially offering new insights into obesity treatment and the psychological aspects of eating behaviors.

30 Nov 2023

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

The study investigates the role of epigenetic changes in GLP1R gene polymorphisms on metabolically healthy obesity (MHO), revealing that apart from genetic variations, DNA methylation significantly influences the occurrence of MHO.

20 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

22 Oct 2023

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Researchers investigate if oat polar lipid compounds improve glucose tolerance, gut hormonal responses, and triglyceridemia.

20 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

10 Aug 2023

Unlocking the potential of Reg3γ: new insights into its metabolic functions and therapeutic prospects

Researchers evaluated the physiological roles of an antimicrobial peptide.

3 Aug 2023

Timing, type, and frequency of exercise are crucial components for optimal glycemic control in type 2 diabetes

Exercise plays a crucial role in managing type 2 diabetes, offering potential benefits such as improved glycemic control. This study explores exercise recommendations and their impact on dietary, medication, and behavioral factors for optimal diabetes care.

5 Jul 2023

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

Researchers performed a double-blinded, placebo-controlled phase III randomized clinical trial (RCT).

29 Jun 2023

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Researchers performed a phase II randomized clinical trial (RCT).